Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 9.94B 8.91B 8.19B 7.42B 13.87B 944B 14.13B 97.68B 39.21B 497B 37.32B 36.52B 1,566B P/E 2026 *
-68.8x
P/E 2027 * 82.7x
Enterprise Value 9.42B 8.43B 7.76B 7.03B 13.14B 894B 13.38B 92.51B 37.13B 470B 35.34B 34.59B 1,483B EV / Sales 2026 *
6.16x
EV / Sales 2027 * 4.25x
Free-Float
94.17%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week-0.89%
1 month-14.60%
3 months-7.91%
6 months-16.82%
Current year-26.10%
1 week 425
Extreme 424.995
445.66
1 month 425
Extreme 424.995
505
Current year 416.21
Extreme 416.21
598.79
1 year 399
Extreme 399
615
3 years 133.98
Extreme 133.985
615
5 years 52.33
Extreme 52.33
615
10 years 13.09
Extreme 13.0886
615
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Director/Board Member 74 2016-06-30
Director/Board Member 68 2016-08-10
Director/Board Member 64 2019-06-26
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 Sell

Chief Executive Officer

-5,221 0.0226%
8/17/26 Sell

General Counsel

-664 0.0029%
8/15/26 Free

Director

1,725 0.0075%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%-0.89%+2.74%+227.57% 9.94B
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.27%+6.70%+43.09%+198.25% 40.43B
Weighted average by Cap. +0.17%+5.29%+46.88%+177.92%

Financials

2026 *2027 *
Net sales 1.53B 1.37B 1.26B 1.14B 2.13B 145B 2.17B 15.01B 6.03B 76.32B 5.73B 5.61B 241B 2.12B 1.9B 1.75B 1.58B 2.96B 201B 3.02B 20.84B 8.37B 106B 7.96B 7.79B 334B
Net income -182M -163M -150M -136M -254M -17.28B -259M -1.79B -718M -9.09B -683M -669M -28.67B 171M 153M 141M 128M 239M 16.26B 243M 1.68B 675M 8.55B 643M 629M 26.98B
Net Debt -527M -472M -434M -393M -735M -50.03B -749M -5.18B -2.08B -26.32B -1.98B -1.94B -83B -924M -828M -761M -690M -1.29B -87.73B -1.31B -9.08B -3.64B -46.15B -3.47B -3.39B -146B
Projected Income Statement - Annual - Madrigal Pharmaceuticals, Inc.
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
26-10-30 $430.36 -0.31% 251,657
26-10-29 $431.70 +0.16% 268,025
26-10-28 $431.00 -2.12% 297,529
26-10-27 $440.33 +0.59% 209,579
26-10-26 $437.74 +0.81% 275,872
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Madrigal Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
430.36USD
Average target price
685.22USD
Spread / Average Target
+59.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Madrigal Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. MDGL Stock